Access the full text.
Sign up today, get DeepDyve free for 14 days.
J. Bartlett, Fiona Campbell, M. Ibrahim, P. Wencyk, I. Ellis, E. Kay, Y. Connolly, A. O'Grady, S. Palma, J. Starczynski, J. Morgan, B. Jasani, K. Miller (2009)
Chromogenic in situ hybridization: a multicenter study comparing silver in situ hybridization with FISH.American journal of clinical pathology, 132 4
J. Bartlett, Fiona Campbell, M. Ibrahim, J. Thomas, P. Wencyk, I. Ellis, E. Kay, Y. Connolly, A. O'Grady, S. Barnett, J. Starczynski, P. Cunningham, K. Miller (2010)
A UK NEQAS ICC and ISH multicentre study using the Kreatech Poseidon HER2 FISH probe: intersite variation can be rigorously controlled using FISHHistopathology, 56
Anja Brügmann, G. Lelkaitis, S. Nielsen, Kirsten Jensen, V. Jensen (2011)
Testing HER2 in Breast Cancer: A Comparative Study on BRISH, FISH, and IHCApplied Immunohistochemistry & Molecular Morphology, 19
E. Perez, V. Suman, N. Davidson, S. Martino, P. Kaufman, W. Lingle, P. Flynn, J. Ingle, D. Visscher, R. Jenkins (2006)
HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 19
Antonio Wolff, M. Hammond, Jared Schwartz, K. Hagerty, D. Allred, Richard Cote, M. Dowsett, P. Fitzgibbons, Wedad Hanna, A. Langer, L. McShane, S. Paik, M. Pegram, Edith Perez, Michael Press, A. Rhodes, C. Sturgeon, S. Taube, R. Tubbs, Gail Vance, Marc Vijver, Thomas Wheeler, Daniel Hayes (2006)
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.Archives of pathology & laboratory medicine, 131 1
Antonio Wolff, M. Hammond, David Hicks, M. Dowsett, Lisa Mcshane, Kimberly Allison, D. Allred, John Bartlett, M. Bilous, P. Fitzgibbons, W. Hanna, Robert Jenkins, P. Mangu, S. Paik, Edith Perez, Michael Press, Patricia Spears, Gail Vance, G. Viale, Daniel Hayes (2014)
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.Archives of pathology & laboratory medicine, 138 2
A. Mansfield, W. Sukov, J. Eckel-Passow, Y. Sakai, Frank Walsh, Melissa Lonzo, A. Wiktor, A. Dogan, R. Jenkins (2013)
Comparison of fluorescence in situ hybridization (FISH) and dual-ISH (DISH) in the determination of HER2 status in breast cancer.American journal of clinical pathology, 139 2
J. Starczynski, N. Atkey, Yvonne Connelly, T. O'grady, Fiona Campbell, S. Palma, P. Wencyk, B. Jasani, M. Gandy, J. Bartlett (2012)
HER2 gene amplification in breast cancer: a rogues' gallery of challenging diagnostic cases: UKNEQAS interpretation guidelines and research recommendations.American journal of clinical pathology, 137 4
W. Hanna, J. Rüschoff, M. Bilous, R. Coudry, M. Dowsett, R. Osamura, F. Penault-Llorca, M. Vijver, G. Viale (2014)
HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneityModern Pathology, 27
Introduction:The most widely used methods for determination of HER2/neu status in breast carcinoma are immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH). Both techniques are associated with technical and interpretive difficulties. Alternative methods exist including quantitative PCR and the newly developed chromogenic dual in situ hybridization (DISH).Methods:We evaluated HER2 DISH as an alternative to FISH and report our findings from 101 cases. In addition, we correlated HER2 DISH and FISH results with HercepTest and 4B5 immunohistochemistry.Results:Eight cases failed FISH analysis and none failed DISH analysis. A 95% (88/93) concordance was found between DISH and FISH for all cases in the series. When only 2+ IHC cases were evaluated, the concordance was 94% for DISH and FISH. Using the 2013 ASCO/CAP recommendations, none of the tested cases were equivocal by FISH or DISH despite 66% of cases being 2+ by HercepTest and 32% by the 4B5 antibody.Comment:Our study, which utilizes a majority of IHC equivocal cases, demonstrates that HER2 FISH and DISH are concordant methodologies. HER2 DISH is therefore an acceptable alternative to FISH.
Applied Immunohistochemistry & Molecular Morphology – Wolters Kluwer Health
Published: Apr 1, 2017
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.